RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+15.08%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$810M
AUM Growth
+$146M
Cap. Flow
+$85.4M
Cap. Flow %
10.54%
Top 10 Hldgs %
36.98%
Holding
72
New
23
Increased
22
Reduced
9
Closed
15
Avg Time Held Equity + Options
0.2 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.2 years
Avg Time Held Equity only
0.2 years
Top 10 Avg Time Held Equity only
0.1 years
Top 20 Avg Time Held Equity only
0.2 years

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$32.8M
2
BMY icon
Bristol-Myers Squibb
BMY
+$20.4M
3
INCY icon
Incyte
INCY
+$19.5M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$18.9M
5
AGN
Allergan Inc
AGN
+$18.8M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$38.7M
2
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$28.8M
3
STJ
St Jude Medical
STJ
+$25.8M
4
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
+$23.3M
5
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$23.3M

Sector Composition

Rank Sector Weight
1 Healthcare 86.06%
2 Miscellaneous 12.08%
3 Consumer Staples 1.18%
4 Technology 0.55%
5 Communication Services 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
GILD icon
1
Gilead Sciences
GILD
$190B
$48.6M 6%
647,287
+117,487
+22% +$8.18M
2013 Q3
1 quarter
CLVS
2
DELISTED
Clovis Oncology, Inc.
CLVS
$34.5M 4.26%
572,270
+100,925
+21% +$5.49M
2013 Q2
2 quarters
ZBH icon
3
Zimmer Biomet
ZBH
$17.5B
$34.3M 4.23%
+378,669
New +$32.8M
2013 Q4
0 quarters
CELG
4
DELISTED
Celgene Corp
CELG
$30.9M 3.82%
366,036
+168,836
+86% +$13.4M
2013 Q2
2 quarters
AZN icon
5
AstraZeneca
AZN
$251B
$30.3M 3.74%
511,120
+275,020
+116% +$14.9M
2013 Q3
1 quarter
AGN
6
DELISTED
Allergan plc
AGN
$28.9M 3.57%
172,240
-99,260
-37% -$15.5M
2013 Q3
1 quarter
PBYI icon
7
Puma Biotechnology
PBYI
$527M
$23.9M 2.95%
230,673
-109,492
-32% -$6.43M
2013 Q2
2 quarters
JAZZ icon
8
Jazz Pharmaceuticals
JAZZ
$13.6B
$23.1M 2.85%
+182,561
New +$18.9M
2013 Q4
0 quarters
INCY icon
9
Incyte
INCY
$22.6B
$22.7M 2.81%
+448,998
New +$19.5M
2013 Q4
0 quarters
ARRY icon
10
DELISTED
Array Biopharma Inc
ARRY
$22.3M 2.76%
4,460,688
+791,095
+22% +$4.31M
2013 Q2
2 quarters
AGN
11
DELISTED
Allergan Inc
AGN
$22.2M 2.74%
199,727
+197,100
+7,503% +$18.8M
2013 Q2
2 quarters
GMED icon
12
Globus Medical
GMED
$10.2B
$21.9M 2.71%
1,086,637
+350,537
+48% +$6.51M
2013 Q2
2 quarters
BMY icon
13
Bristol-Myers Squibb
BMY
$121B
$21.3M 2.63%
+400,870
New +$20.4M
2013 Q4
0 quarters
HTWR
14
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$20.9M 2.57%
222,023
+36,898
+20% +$3.12M
2013 Q2
2 quarters
KYTH
15
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$20.8M 2.56%
557,761
+329,543
+144% +$13.7M
2013 Q2
2 quarters
FOLD icon
16
DELISTED
Amicus Therapeutics
FOLD
$20.3M 2.51%
8,648,087
+6,174,300
+250% +$13.6M
2013 Q2
2 quarters
HCA icon
17
HCA Healthcare
HCA
$102B
$20M 2.47%
419,100
+4,700
+1% +$217K
2013 Q2
2 quarters
THC icon
18
Tenet Healthcare
THC
$21.9B
$19.4M 2.4%
461,402
-129,598
-22% -$5.64M
2013 Q2
2 quarters
OXFD
19
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$18.3M 2.26%
+946,457
New +$16.7M
2013 Q4
0 quarters
ICPT
20
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$18.2M 2.24%
+265,949
New +$15.4M
2013 Q4
0 quarters
RCPT
21
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$18.1M 2.24%
625,133
+604,333
+2,905% +$16.2M
2013 Q3
1 quarter
NUVA
22
DELISTED
NuVasive, Inc.
NUVA
$17.8M 2.2%
550,914
-142,478
-21% -$4.28M
2013 Q2
2 quarters
UHS icon
23
Universal Health Services
UHS
$11B
$16.7M 2.06%
+205,300
New +$16.4M
2013 Q4
0 quarters
PFE icon
24
Pfizer
PFE
$166B
$16.4M 2.03%
+564,944
New +$16.4M
2013 Q4
0 quarters
ARAY icon
25
Accuray
ARAY
$20.9M
$15.2M 1.88%
1,744,811
+671,012
+62% +$5.21M
2013 Q3
1 quarter
1
2 3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2013 Portfolio in Review

As of Q4 2013, Redmile Group held 72 positions worth $810M, up 22% from $664M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Redmile Group deployed $85.4M of net new capital in Q4 2013, opening 23 new positions and adding to 22 existing holdings. Its largest new stake was Zimmer Biomet: 378,669 shares worth $34.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was St Jude Medical, an estimated $25.8M trimmed.

  • Redmile Group's largest Q4 2013 buy was Zimmer Biomet: 378,669 shares worth $34.3M.
  • Redmile Group added most to Allergan Inc in Q4 2013, an estimated $18.8M increase.
  • Redmile Group's biggest Q4 2013 reduction was St Jude Medical, cutting an estimated $25.8M.
  • Redmile Group fully exited Amgen in Q4 2013, selling an estimated $38.7M.
  • Redmile Group's ten largest holdings make up 37% of its $810M portfolio in Q4 2013.
  • Redmile Group opened 23 new positions and closed 15 in Q4 2013.
  • Redmile Group's portfolio value rose 22% quarter-over-quarter to $810M.

Based on Redmile Group's 13F filing for Q4 2013, filed 14 Feb 2014.